MAIA Biotechnology announced positive initial efficacy data from its Phase 2 THIO-101 Part C trial for advanced non-small cell lung cancer (NSCLC), showing a 90.5% disease control rate in heavily pre-treated patients. The trial tests ateganosine followed by cemiplimab, a combination that significantly outperforms standard chemotherapy's 25-35% control rate. This treatment targets telomeres to induce cancer cell death and boost immune response. The company has completed international enrollment and reports an acceptable safety profile, advancing a promising option for patients resistant to current therapies.
Mint Innovation appointed Matt Bedingfield as Global CEO and spun off its lithium-ion battery recovery business into a new company called Linca, led by co-founder Dr. Ollie Crush. This move allows Mint to concentrate on recovering metals from printed...
Sandler, part of Trilliad, introduced the Sales Performance Ecosystem, the first platform to evaluate sales skills during actual buyer conversations using AI-powered coaching. This system links training directly to revenue by measuring real behavior ...
Pacira BioSciences awarded inducement grants to 10 new employees, including stock options for 9,200 shares and restricted stock units for 18,200 shares, as part of its Amended 2014 Inducement Plan. These awards, approved by the company's compensation...
German insurance company Allianz announced plans to cut between 1,500 and 1,800 jobs in Europe, mainly affecting call center roles at its subsidiary Allianz Partners. This move is part of Allianz's strategy to increase the use of artificial intellige...
Shell Plc's Q2 update led brokers like Citi and Jefferies to raise earnings forecasts by 13-14%, driven by strong oil trading, improved chemical margins, and resilient fuels marketing. Citi noted these gains are likely temporary but expects cash flow...
